Daily Stock Opinions and Ratings

Opinions

Peter HodsonAfexa Life Sciences Inc.FXA.TODON'T BUYDec 28, 2006

Started launching ColdFX in the US and want to go through the full trial process to get approval as to what they can claim on the product. Expensive stock.

Peter Hodson

Unlock Rating

$2.81

Stock price when the opinion was issued

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

COMMENT

A marketing company. A little bit of controversy. Want to label their product in the US. Never enthralled with marketing companies. Costs a lot of money and you are at the mercy of the vagueness of the consumer.

HOLD

Manufactures ColdFX. Loves the product, but a little concerned about the share price. Revenues are considerably smaller than the market cap. A little ahead of itself.

BUY

Had a long drop from December to May which was followed by a number of upward steps. Those are very important levels and he thinks the stock probably has more positive news in it. Every time there is a rally, there is a lot of volume with it.

DON'T BUY

Great product. Watch for fads. Great marketing company.

WATCH

A very interesting company. Using ginseng extract to create a remedy for colds. (ColdFX) The product has just taken off. Still looking at it. If they go into the US, it could be a big boost. Might be a little expensive here.

DON'T BUY

Stock has had a huge run. Huge growth opportunity.Product ColdFX seems to be working very well. Negative is that it is trading at about 31 X sales. Very high risk.

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Peter HodsonAfexa Life Sciences Inc.FXA.TODON'T BUYDec 28, 2006

You might be interested:

Afexa Life Sciences Inc.(FXA.TO)

Afexa Life Sciences Inc.(FXA.TO)

Afexa Life Sciences Inc.(FXA.TO)

Afexa Life Sciences Inc.(FXA.TO)

Afexa Life Sciences Inc.(FXA.TO)

Afexa Life Sciences Inc.(FXA.TO)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Jim Cramer - Mad Money

Richard Orrell

Stockchase Insights

The Panic-Proof Portfolio (Stockchase Research)

Stan Wong